Will EyePoint announce topline results from the LUCIA trial of DURAVYU in wet age-related macular degeneration by December 31, 2026?
deadline 2026-12-31
confidence medium
tier 4 evidence
57%PolySignal estimate
Resolution criterion
Yes if, no later than December 31, 2026, EyePoint publicly reports the topline results of the LUCIA trial of DURAVYU (the outcome on the primary endpoint, positive or negative) in a press release or SEC filing. The deadline is the last day of the period the company gave in its filing ("fourth quarter of 2026"). An announcement of a delay or of a new timeline, enrollment or interim data that do not report the primary-endpoint outcome, or the absence of any announcement by that date, resolves NO.
Verified starting state
As of October 11, 2026: according to the EyePoint filing of August 17, 2026, the company expects topline results in the period "fourth quarter of 2026". Source: https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm
What pushes it up
- EyePoint’s August 17, 2026 SEC filing states the company expects topline results in Q4 2026 (tier 1)
What pushes it down
- Multiple tier‑4 articles (indices 0‑4) report mixed or negative results and suggest the trial may have already failed or been delayed, but lack higher‑tier corroboration
- Absence of any tier‑1 or tier‑2 confirmation that results have been released yet
What would move this number most
A tier‑1 or tier‑2 source confirming that the LUCIA trial results have been released (or delayed) would most shift the estimate
How this number is built
| Deadline | 2026-12-31 |
| Base rate | 55% |
| Best evidence | tier 4 · 5 article(s) used |
| Independent runs | 52 · 62 (spread 10 pts) |
| Confidence | medium |
| Evidence cap | not triggered |
| Last revised | 2026-10-12 16:00 |
| Model | openai/gpt-oss-120b (Groq) |
Sources consulted